Theravance Biopharma, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update

Rhea-AI Summary

Theravance Biopharma (TBPH) reported Q1 2021 total revenue of $14.3 million, a decrease of $5.6 million YOY, attributed mainly to collaboration revenue from Viatris. While YUPELRI's market share grew to 19%, overall net sales faced a slight decline. R&D expenses increased to $67.6 million, leading to an operating loss of $83.9 million. The company anticipates full-year R&D expenses between $195 million and $225 million. Notable upcoming clinical milestones include results for nezulcitinib and izencitinib trials expected in Q2 and Q3 2021.

Positive

• YUPELRI's market share increased to 19% in January 2021.
• TRELEGY reported Q1 2021 global net sales of $341 million, a 36.9% increase YOY.

Negative

• Q1 2021 total revenue decreased by $5.6 million compared to Q1 2020.
• Operating loss increased to $83.9 million from $72.5 million year-over-year.

DUBLIN, May 4, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the first quarter of 2021.

"2021 is on track to be a transformational year as we make significant progress towards our business goals," said Rick E Winningham, Chief Executive Officer. "Our commercial assets provide cash flow to invest in our diversified clinical pipeline. GSK's TRELEGY continues an exceptional, unabated growth trajectory. Our YUPELRI team, with our partner Viatris, continues to drive performance despite pandemic-associated headwinds. While we experienced slightly down sequential quarter-over-quarter net sales results, our January 2021 market share was 19%—its highest level since launch—and we ended the quarter on a strong note with March volume demand demonstrating 28% growth over February."

"Additionally, we are focused on advancing development of our innovative and differentiated pipeline. We continue to progress nezulcitinib, our wholly-owned nebulized lung-selective pan-JAK inhibitor, our potentially best-in-class ampreloxetine for symptomatic neurogenic orthostatic hypotension and izencitinib, our oral gut-selective pan-JAK inhibitor for inflammatory bowel disease that is partnered with Janssen Pharmaceuticals. Our team is looking forward to four significant clinical readouts between now and Q1 2022: our Phase 2 nezulcitinib trial in Q2, our Phase 3 ampreloxetine and Phase 2b izencitinib Ulcerative Colitis trials each in Q3, and the Phase 2 izencitinib Crohn's disease trial in Q4/Q1 2022. We remain committed to delivering each of these clinical data sets with the highest quality as expeditiously as possible."

Upcoming Clinical Milestones

• Q2 2021: Nezulcitinib (nebulized lung-selective pan-Janus kinase (JAK) inhibitor) Phase 2 for acute hyperinflammation of the lung in COVID-19 (study 0188) – enrollment complete and topline results expected in Q2.
• Q3 2021: Ampreloxetine (norepinephrine reuptake inhibitor) Phase 3 for symptomatic neurogenic orthostatic hypotension (study 0169) – enrollment near complete and topline results expected in Q3.
• Q3 2021: Izencitinib (gut-selective oral pan-JAK inhibitor for inflammatory intestinal diseases) Phase 2b in ulcerative colitis (study 0157) – enrollment complete and topline results expected in Q3.
• Q4 2021/Q1 2022: Izencitinib (gut-selective oral pan-JAK inhibitor for inflammatory intestinal diseases) due to enrollment challenges, Phase 2 in Crohn's disease (study 0173) – enrollment ongoing and topline results now expected in late Q4 2021/early Q1 2022.

Quarterly Highlight

• YUPELRI^® (revefenacin) inhalation solution, the first and only once-daily, nebulized bronchodilator approved in the U.S. for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), continued to increase its share of the long-acting nebulized COPD market, increasing to 19.0% in January 2021, up from 18.6% in December 2020.

Economic Interest

• TRELEGY (first once-daily single inhaler triple therapy for COPD and asthma), in which the Company holds an economic interest, posted first quarter 2021 global net sales of $341 million (up from $249 million, 36.9%, in the first quarter of 2020); Theravance Biopharma is entitled to tiered royalties of 5.5% to 8.5% of TRELEGY global net sales.³

First Quarter Financial Results  

• Revenue: Total revenue for the first quarter of 2021 was $14.3 million, comprised of non-cash collaboration revenue of $3.9 million primarily attributed to our global collaboration with Janssen and $10.4 million in Viatris collaboration revenue. Total revenue for the first quarter represents a $5.6 million decrease over the same period in 2020.
• YUPELRI: The Viatris collaboration revenue of $10.4 million for the first quarter of 2021 represents amounts receivable from Viatris and is comprised of the Company's 35% share of net sales of YUPELRI as well as its proportionate amount of the total shared costs incurred by the two companies. The non-shared YUPELRI costs incurred by Theravance Biopharma are recorded within operating expenses. While Viatris records the total net sales of YUPELRI within its financial statements, our implied 35% share of net sales of YUPELRI for the first quarter of 2021 was $12.9 million.
• Research and Development (R&D) Expenses: R&D expenses for the first quarter of 2021 were $67.6 million, compared to $66.0 million in the same period in 2020. First quarter R&D expenses included total non-cash share-based compensation of $7.9 million.
• Selling, General and Administrative (SG&A) Expenses: SG&A expenses for the first quarter of 2021 were $30.6 million, compared to $26.3 million in the same period in 2020. First quarter SG&A expenses included total non-cash share-based compensation of $7.9 million.
• Operating Loss: Operating loss for the first quarter of 2021 was $83.9 million compared to $72.5 million in the same period of 2020.
• Cash Position: Cash, cash equivalents and marketable securities totaled $210.0 million as of March 31, 2021.

2021 Financial Guidance

• Operating Expenses (excluding share-based compensation): The Company expects full year 2021 R&D expense of $195 million to $225 million, and SG&A expense of $80 million to $90 million.

Conference Call and Live Webcast Today at 5 pm ET

Theravance Biopharma will hold a conference call and live webcast accompanied by slides today at 5 pm ET / 2 pm PT / 10 pm IST. To participate, please dial (855) 296-9648 from the U.S. or (920) 663-6266 for international callers, using the confirmation code 1092615. Those interested in listening to the conference call live via the internet may do so by visiting Theravance.com, under the Investors section, Presentations and Events.

A replay will be available on Theravance.com for 30 days through June 3, 2021. An audio replay will also be available through 8:00 pm ET on May 11, 2021, by dialing (855) 859-2056 from the U.S., or (404) 537-3406 for international callers, and then entering confirmation code 1092615.

About Theravance Biopharma

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.

In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI^® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs.

Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY.

For more information, please visit www.theravance.com.

THERAVANCE BIOPHARMA®, THERAVANCE®, and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

YUPELRI^® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trade names or service marks of other companies appearing on this press release are the property of their respective owners

This press release contains and the conference call will contain certain "forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, expectations and future events. Theravance Biopharma intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Examples of such statements include statements relating to: the Company's goals, designs, strategies, plans and objectives, the Company's regulatory strategies and timing of clinical studies (including the data therefrom), the potential characteristics, benefits and mechanisms of action of the Company's product and product candidates, the potential that the Company's research programs will progress product candidates into the clinic, the Company's expectations for product candidates through development, the Company's expectations regarding its allocation of resources, potential regulatory approval and commercialization (including their differentiation from other products or potential products), product sales or profit share revenue and the Company's expectations for its expenses, excluding share-based compensation and other financial results. These statements are based on the current estimates and assumptions of the management of Theravance Biopharma as of the date of the press release and the conference call and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Theravance Biopharma to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: disagreements with Innoviva, Inc. and TRC LLC, the uncertainty of arbitration and litigation and the possibility that the results of these proceedings could be adverse to the Company, delays or difficulties in commencing, enrolling or completing clinical studies, the potential that results from clinical or non-clinical studies indicate the Company's compounds or product candidates are unsafe or ineffective, risks that product candidates do not obtain approval from regulatory authorities, the feasibility of undertaking future clinical trials for our product candidates based on policies and feedback from regulatory authorities, dependence on third parties to conduct clinical studies, delays or failure to achieve and maintain regulatory approvals for product candidates, risks of collaborating with or relying on third parties to discover, develop, manufacture and commercialize products, and risks associated with establishing and maintaining sales, marketing and distribution capabilities with appropriate technical expertise and supporting infrastructure. In addition, while we expect the effects of COVID-19 to continue to adversely impact our business operations and financial results, the extent of the impact on our ability to generate revenue from YUPELRI® (revefenacin), our clinical development programs (including but not limited to our later stage clinical programs for izencitinib and ampreloxetine), and the value of and market for our ordinary shares, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time. These potential future developments include, but are not limited to, the ultimate duration of the COVID-19 pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States and in other countries, other measures taken by us and those we work with to help protect individuals from contracting COVID-19, and the effectiveness of actions taken globally to contain and treat the disease, including vaccine availability, distribution, acceptance and effectiveness. Other risks affecting Theravance Biopharma are in the Company's Form 10-K filed with the SEC on February 26, 2021 and other periodic reports filed with the SEC. In addition to the risks described above and in Theravance Biopharma's filings with the SEC, other unknown or unpredictable factors also could affect Theravance Biopharma's results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Theravance Biopharma assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.

Contact: Gail B. Cohen
Corporate Communications
917-214-6603

¹ While Viatris Inc. ("Viatris") records the total YUPELRI net sales, the Company is entitled to a 35% share of the profits and losses pursuant to a co-promotion agreement with Viatris.

² As reported by Glaxo Group Limited or one of its affiliates (GSK); reported sales converted to USD; economic interest related to TRELEGY (the combination of fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI), jointly developed by GSK and Innoviva, Inc.) entitles the Company to upward tiering payments equal to approximately 5.5% to 8.5% on worldwide net sales of the product (net of Theravance Respiratory Company, LLC (TRC) expenses paid and the amount of cash, if any, expected to be used in TRC over the next four fiscal quarters). 75% of the income from the Company's investment in TRC is pledged to service outstanding notes and 25% of income from the Company's investment in TRC is retained by the Company.

³ As reported by Glaxo Group Limited or one of its affiliates (GSK); reported sales converted to USD; economic interest related to TRELEGY (the combination of fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI), jointly developed by GSK and Innoviva, Inc.) entitles the Company to upward tiering payments equal to approximately 5.5% to 8.5% on worldwide net sales of the product (net of Theravance Respiratory Company, LLC (TRC) expenses paid and the amount of cash, if any, expected to be used in TRC over the next four fiscal quarters). 75% of the income from the Company's investment in TRC is pledged to service outstanding notes and 25% of income from the Company's investment in TRC is retained by the Company.

 

THERAVANCE BIOPHARMA, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
	March 31,			December 31,
	2021			2020
Assets	(Unaudited)			(1)
Current assets:
Cash and cash equivalents and short-term marketable securities	$	209,968		$	292,941
Receivables from collaborative arrangements		11,915			15,868
Receivables from licensing arrangements		-			-
Amounts due from TRC, LLC		42,359			53,799
Prepaid clinical and development services		18,792			20,374
Other prepaid and current assets		10,037			10,359
Total current assets		293,071			393,341
Property and equipment, net		16,944			16,422
Operating lease assets		42,517			43,260
Equity in net assets of TRC, LLC		19,439			12,750
Restricted cash		833			833
Other assets		2,304			2,451
Total assets	$	375,108		$	469,057
Liabilities and Shareholders' Deficit
Current liabilities	$	86,492		$	123,571
Convertible senior notes due 2023, net		227,230			226,963
Non-recourse notes due 2035, net		375,181			372,873
Long-term operating lease liabilities		57,026			47,220
Other long-term liabilities		2,397			2,181
Shareholders' deficit		(373,218)			(303,751)
Total liabilities and shareholders' deficit	$	375,108		$	469,057
________________________________

(1)  The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020.

 

	THERAVANCE BIOPHARMA, INC.
	CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
	(In thousands, except per share data)
			Three Months Ended March 31,
			2021			2020
			(Unaudited)
	Revenue:
	Collaboration revenue		$	3,872		$	6,632
	Licensing revenue			-			1,500
	Viatris collaboration agreement			10,385			11,730
	Total revenue			14,257			19,862
	Costs and expenses:
	Research and development (1)			67,599			66,013
	Selling, general and administrative (1)			30,550			26,325
	Total costs and expenses			98,149			92,338
	Loss from operations			(83,892)			(72,476)
	Income from investment in TRC, LLC			16,547			13,515
	Interest expense			(11,873)			(9,941)
	Loss on extinguishment of debt			-			(15,464)
	Interest and other income, net			(234)			1,460
	Loss before income taxes			(79,452)			(82,906)
	Provision for income tax expense			(227)			(147)
	Net loss		$	(79,679)		$	(83,053)
	Net loss per share:
	Basic and diluted net loss per share		$	(1.24)		$	(1.40)
	Shares used to compute basic and diluted net loss per share			64,493			59,463
	________________________________
	(1)Amounts include share-based compensation expense as follows:
			Three Months Ended March 31,
	(In thousands)		2021			2020
	Research and development		$	7,921		$	7,865
	Selling, general and administrative			7,911			7,411
	Total share-based compensation expense		$	15,832		$	15,276

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/theravance-biopharma-inc-reports-first-quarter-2021-financial-results-and-provides-business-update-301283716.html

SOURCE Theravance Biopharma, Inc.

FAQ

What were Theravance Biopharma's Q1 2021 financial results?

Theravance Biopharma reported total revenue of $14.3 million for Q1 2021, down $5.6 million YOY, with an operating loss of $83.9 million.

What is the expected timeline for Theravance Biopharma's clinical milestones?

The company expects trial results for nezulcitinib in Q2 2021 and izencitinib in Q3 2021.

How did YUPELRI perform in the market in January 2021?

YUPELRI's market share reached 19% in January 2021, up from 18.6% in December 2020.

What is the financial guidance for Theravance Biopharma in 2021?

The company expects full-year R&D expenses to be between $195 million and $225 million, and SG&A expenses of $80 million to $90 million.